A recent study identified three clinical subgroups of patients with anti-SRP immune mediated necrotizing myopathy (anti-SRP IMNM).
Anti-SRP IMNM is a rare autoimmune disorder characterized by muscle weakness and necrosis in the proximal muscles. The exact cause of this condition is unknown.
The goal of this retrospective study was to identify clinical subgroups within the anti-SRP IMNM patient population to help facilitate management of the disease. Following the collection of clinical data, cluster analyses classified distinct subgroups based on patients’ clinical features. Statistical analyses then compared clinical characteristics and outcomes among the identified clusters.
In total, 116 patients were included, with 3 distinct clinical subgroups identified. Cluster 3 included acute patients, Cluster 2 included subacute patients, and Cluster 1 included patients with poor prognosis.
Distinct features of the patients within Cluster 3 included a short disease course at a median of 3 months, severe muscle weakness, high muscle enzyme levels, and a good response to treatment. Distinct features of Cluster 2 included a younger patient population with a mean age of 45.83 years, longer disease course at a median of 6.5 months, milder muscle damage, and lower autoantibody titers. Distinct features of Cluster 1 included an older patient population with a mean age of 58.1 years, predominantly male patients, higher incidences of interstitial lung disease and cardiac injury, higher rates of refractory cases, and a higher relapse rate.
The results from this study highlight the clinical heterogeneity of patients with anti-SRP IMNM by identifying three distinct subgroups and their characteristics. Findings such as these present the opportunity for more effective personalized disease management for individual patients.
For more information, click here.
To learn more about IMNM and other rare musculoskeletal disorders, visit https://checkrare.com/diseases/musculoskeletal-diseases/
